Table 2 The sensitivity of DMRTA2 by different types of disease in urine samples

Bladder cancer

137

117

85.4% (78.1–90.6%)

79

62

78.5% (67.5–86.6%)

216

179

82.9% (77.0–87.5%)

Carcinomas of renal pelvis

23

18

78.3% (55.8–91.7%)

12

11

91.7% (59.8–99.6%)

35

29

82.9% (65.7–92.8%)

Carcinomas of ureter

13

7

53.8% (26.1–79.6%)

6

3

50.0% (13.9–86.1%)

19

10

52.6% (29.5–74.8%)

Renal carcinomas

31

0

0

40

2

5.0% (0.8–18.2%)

71

2

2.8% (0.5–10.7%)

Prostate cancers

13

1

7.7% (0.4–37.9%)

49

5

10.2% (3.8–23.0%)

62

6

9.7% (4–20.5%)

Benign tumors of bladder

28

3

10.7% (2.8–29.4%)

22

7

31.8% (14.7–54.9%)

50

10

20.0% (10.5–34.1%)

Recurring cancers

22

17

77.3% (54.2–91.3%)

8

7

87.5% (46.7–99.3%)

30

24

80.0% (60.8–91.6%)

Specificity

Specificity

Specificity

202

14

93.1%^b (88.4–96.0%)

304

24

92.1%^b (88.3–94.8%)

506

38

92.5%^b (89.7–94.6%)